Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alnylam, CSIRO, Cerulean, and More


Title: Treating Picornavirus Infection by Targeting microRNA miR-141

Patent Number: 8,263,570

Filed: Dec. 15, 2009

Lead Inventor: Bing-Ching Ho, National Taiwan University

The invention, the patent's abstract states, involves treating “picornavirus infection by inhibiting miR-141 activity. Also disclosed herein are a method for [identifying] miR-141 inhibitory compounds and a method for identifying a target viral infection to be treated by anti-miR-141 therapy.”

Title: Gene Silencing of the Brother of the Regulator of Imprinted Sites

Patent Number: 8,263,571

Filed: Aug. 11, 2008

Lead Inventor: Boris Reznik, Vendevia Group

The invention, the patent's abstract states, “provides methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, brother of the regulatory of imprinted sites … [or] BORIS ... by RNA interference. Methods of the ... invention can be used to silence BORIS in cancer cells, which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy.”

Title: RNAi Modulation of RSV and Therapeutic Uses Thereof

Patent Number: 8,263,572

Filed: June 14, 2008

Inventor: Rachel Meyers, Alnylam Pharmaceuticals

The invention is based on “the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents,” according to the patent's abstract. “Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the ... invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels, and viral titers in a subject. ... These findings can be applied to other respiratory viruses.”

Title: Delivery of dsRNA to Arthropods

Patent Number: 8,263,573

Filed: Sept. 23, 2011

Lead Inventor: Steven Whyard, Commonwealth Scientific and Industrial Research Organization

“The invention is to methods of gene silencing in arthropods using dsRNA,” the patent's abstract states. “The method [includes] contacting the arthropod with, and/or directly feeding the arthropod, the dsRNA ... to deliver the dsRNA to arthropod tissues. It is envisaged that the methods of the invention will have use in determining the biological function of genes in arthropods. Methods of pest control of arthropods, and of protecting arthropods against parasites and predators, are provided. Transgenic arthropods expressing dsRNA molecules are also provided.”

Title: Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Usage Thereof

Patent Number: 8,263,761

Filed: Jan. 10, 2011

Lead Inventor: Zhiwen Zhou, Beijing Solobio Genetechnology

“The invention provides a group of nucleic acid fragments … for prevention of HIV infection or AIDS and the usage thereof,” the patent's abstract states. “In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained by homology [comparison]. The double-stranded RNA derived from these fragments can effectively inhibit the expression of the HIV genes. The RNA transcribed by plasmid also can suppress the expression of the HIV in the cell. After the adenovirus or associated virus, which carry DNA corresponding [to the] above RNA, infect the cell, the transcription dsRNA can inhibit the expression of the HIV genes.”

Title: Methods and Compositions for Improved [Delivery], Expression, or Activity of RNA Interference Agents

Application Number: 20120225115

Filed: April 11, 2012

Lead Inventor: Jessie Au, Optimum Therapeutics

The invention, the patent application's abstract states, comprises “methods and compositions for enhanced delivery of siRNA or miRNA into the interior of multi-layered tissues, and into the cytoplasm or nucleus of cells of a tissue. Such methods and compositions yield tumor-selective and intracellular delivery of RNAi agents and allow for RNAi-mediated activity such as knockdown of the target genes and associated products. The current disclosure further provides methods and compositions for improving the intracellular bioavailability of nucleotide agents.”

Title: Conjugates, Particles, Compositions, and Related Methods

Application Number: 20120225129

Filed: Aug. 18, 2011

Lead Inventor: Scott Eliasof, Cerulean Pharma

The patent application, its abstract states, claims “particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both [are also claimed, as are] methods of using the particles, the conjugates, and the compositions.”

Title: Viral and Viral-Associated miRNAs and Uses Thereof

Application Number: 20120225477

Filed: Aug. 4, 2010

Lead Inventor: Issac Bentwich, Rosetta Genomics

The patent application, its abstract states, claims “novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.”

Title: Compositions and Methods for Inhibiting Expression of Transthyretin

Application Number: 20120225927

Filed: March 1, 2012

Lead Inventor: Dinah Sah, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid targeting a transthyretin gene, and methods of using the dsRNA to inhibit expression of TTR,” the patent application's abstract states.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.